Clinical Trial Update: 8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting the completion of an 8-week treatment with DDP225 in adults with diarrhea-predominant irritable bowel syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• DDP225

Snippet

Sponsor: Dynogen Pharmaceuticals | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED